1-year results of a phase 3 trial in 311 people aged 12+ with moderate scalp, genital or hand/foot psoriasis: with once-daily oral icotrokinra, clear/almost clear rates held to week 52 (overall 67–70%; scalp 72–78%; genital 85–90%; hand/foot 54–62%), with no new safety signal.
RCTn = 311
Warren et al. Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings